Fig. 3From: Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in CanadaResults of 5000 simulations from probabilistic analysis a) on the cost-effectiveness plane and b) on a cost-effectiveness acceptability curveBack to article page